

RETAIN BONE... and a sound horse



A product of

CEVA
SANTE ANIMALE

- Proven treatment for Navicular Disease and Bone Spavin
- Excess bone resorption is reduced by active inhibition of osteoclasts
- Tildren regulates bone remodelling with positive effects on bone formation and mineralisation



TILDREN INJECTION

Distributed by:


NATURE VET
Health & Performance

For enquiries and technical support:

NATURE VET PTY LTD

Telephone (+61) 2 9652 7000

Email: info@naturevet.com.au

Web: www.naturevet.com

Treatment for Lameness Associated with Bone and Cartilage Changes in Horses

Composition

Contains: TILUDRONIC ACID 50 mg/vial

Actions

Tiludronic acid belongs to the bisphosphonate therapeutic class, a class of products with activity on bone metabolism. The main pharmacological property of TILDREN Injection is to reduce bone resorption by inhibiting the activity of osteoclasts.

TILDREN Injection acts as a regulator of bone remodelling in all situations involving excessive bone resorption. This regulator effect is not associated with a negative effect on bone formation or bone mineralisation at the recommended therapeutic dosage.

Areas of reduced bone density are a pathological change common to most cases of Navicular Disease and Bone Spavin and are due to inappropriate resorption of bone ("osteolysis"). In double-blind, placebo-controlled clinical trials for both conditions, TILDREN treatment produced clear improvement as demonstrated by long-term reduction in lameness and progressive resumption of sporting activity.

In another double-blind, placebo-controlled clinical trial into the treatment of back pain associated with bony lesions of the vertebral column, TILDREN treatment induced a clear improvement in back flexibility, however further research is required to add this indication as a registered claim. Other studies have shown that TILDREN treatment can prevent the bone loss which usually occurs during inactivity in horses, as shown by measurements of bone density in spelling horses.

TILDREN Injection has also demonstrated anti-arthritic properties in a model of poly-arthritis in rats. *In vitro* data identified inhibiting effects on the secretion of enzymes which degrade cartilage matrix.



Indications

Horses: Treatment of lameness associated with bone and cartilage changes such as those observed in Navicular Disease and Bone Spavin.

Dosage and Administration

Dosage: 0.1 mg Tiludronic acid per kg bodyweight once daily for 10 days
by slow intravenous injection
i.e. 10mL (1 vial) of reconstituted solution per 500 kg bodyweight per day for 10 days.

Short-term side-effects such as benign muscle tremor, sweating or colic may occur in a small proportion of horses in the 1-3 hours following Tiludronic acid injection. These effects generally resolve spontaneously without specific treatment however observation of the horse for 3 hours post-injection is recommended. The incidence of these signs is greatly reduced by slowing down the speed of administration.

A mild local reaction at the site of injection is possible after IV administration of the product but typically disappears within a few days.

Presentation

Carton contains: 10 vials of 50 mg freeze-dried powder (Tildren) and 10 vials of 10 mL solvent (Water for injection).
Each carton provides a 10-day treatment course for a 500 kg horse.

Storage

Store below 25°C (Air conditioning) in outer carton.

Poisons Schedule

S4 - Prescription Animal Remedy

APVMA Approval Number

58057/10/0205 (A product of CEVA Sante Animale)

Warnings

Due to the lack of studies on the adverse effects of Tiludronic acid on the skeleton of young animals, this product is not recommended in horses younger than 2 years of age. Safety in pregnant or lactating mares has not been established. Do not use in horses that may be slaughtered for human consumption.

When administering to competition horses, ensure that the regulations of relevant authorities are observed.